EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing

Amy J Turner iD, Cyrine E Haidar iD, Wenjian Yang iD, Erin C Boone iD, Steven M Offer, Philip E Empey iD, Andrew Haddad iD, Saba Tahir, Gunter Scharer iD, Ulrich Broeckel, Andrea Gaedigk iD

Clinical and Translational Science · 2024-01 · 17 (1)

DOI: 10.1111/cts.13699 ↗

At a glance

Journal article in Clinical and Translational Science, published online on 2024-01-10. Written by Amy J Turner and 10 co-authors. Institution: RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA. Major MEDLINE topics: Dihydrouracil Dehydrogenase (NADP), Population Health. Cited 43 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH HHS, NCI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The DPYD gene encodes dihydropyrimidine dehydrogenase, the rate‐limiting enzyme for the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in DPYD have been associated with altered enzyme activity, therefore accurate detection and interpretation is critical to predict metabolizer status for individualized fluoropyrimidine therapy. The most commonly observed deleterious variation is the causal variant linked to the previously described HapB3 haplotype, c.1129‐5923C>G (rs75017182) in intron 10, which introduces a cryptic splice site. A benign synonymous variant in exon 11, c.1236G>A (rs56038477) is also linked to HapB3 and is commonly used for testing. Previously, these single‐nucleotide polymorphisms (SNPs) have been reported to be in perfect linkage disequilibrium (LD); therefore, c.1236G>A is often utilized as a proxy for the function‐altering intronic variant. Clinical genotyping of DPYD identified a patient who had c.1236G>A, but not c.1129‐5923C>G, suggesting that these two SNPs may not be in perfect LD, as previously assumed. Additional individuals with c.1236G>A, but not c.1129‐5923C>G, were identified in the Children's Mercy Data Warehouse and the All of Us Research Program version 7 cohort substantiating incomplete SNP linkage. Consequently, testing only c.1236G>A can generate false‐positive results in some cases and lead to suboptimal dosing that may negatively impact patient therapy and prospect of survival. Our data show that DPYD genotyping should include the functional variant c.1129‐5923C>G, and not the c.1236G>A proxy, to accurately predict DPD activity.

Subjects

MeSH terms (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)Population HealthChildHumansHaplotypesAntimetabolites, AntineoplasticPharmacogenomic TestingGenotype

Substances

Dihydrouracil Dehydrogenase (NADP)Antimetabolites, Antineoplastic

Authors and institutions

  • RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.

ORCID profiles: Amy J Turner, Cyrine E Haidar, Wenjian Yang, Erin C Boone, Philip E Empey, Andrew Haddad, Gunter Scharer, Andrea Gaedigk

Funding

  • NIH HHS
  • NCI NIH HHS

Cite

APA

Turner, A. J., Haidar, C. E., Yang, W., Boone, E. C., Offer, S. M., Empey, P. E., Haddad, A., Tahir, S., Scharer, G., Broeckel, U., & Gaedigk, A. (2024). Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clinical and Translational Science, 17(1). https://doi.org/10.1111/cts.13699

Vancouver

Turner AJ, Haidar CE, Yang W, Boone EC, Offer SM, Empey PE, et al. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clinical and Translational Science. 2024;17(1). doi:10.1111/cts.13699

BibTeX
@article{Turner2024,
  author = {Turner, Amy J and Haidar, Cyrine E and Yang, Wenjian and Boone, Erin C and Offer, Steven M and Empey, Philip E and Haddad, Andrew and Tahir, Saba and Scharer, Gunter and Broeckel, Ulrich and Gaedigk, Andrea},
  title = {Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1111/cts.13699}
}
Start for free →